Targeting of reactive isolevuglandins in mitochondrial dysfunction and inflammation

Inflammation is a major cause of morbidity and mortality in Western societies. Despite use of multiple drugs, both chronic and acute inflammation still represent major health burdens. Inflammation produces highly reactive dicarbonyl lipid peroxidation products such as isolevuglandins which covalentl...

Full description

Bibliographic Details
Main Authors: Vladimir Mayorov, Peter Uchakin, Venkataraman Amarnath, Alexander V. Panov, Christy C. Bridges, Roman Uzhachenko, Bill Zackert, Christy S. Moore, Sean Davies, Anna Dikalova, Sergey Dikalov
Format: Article
Language:English
Published: Elsevier 2019-09-01
Series:Redox Biology
Online Access:http://www.sciencedirect.com/science/article/pii/S221323171930480X
id doaj-6fedba37fca54e3b8b8d573c435de88a
record_format Article
spelling doaj-6fedba37fca54e3b8b8d573c435de88a2020-11-25T00:02:54ZengElsevierRedox Biology2213-23172019-09-0126Targeting of reactive isolevuglandins in mitochondrial dysfunction and inflammationVladimir Mayorov0Peter Uchakin1Venkataraman Amarnath2Alexander V. Panov3Christy C. Bridges4Roman Uzhachenko5Bill Zackert6Christy S. Moore7Sean Davies8Anna Dikalova9Sergey Dikalov10Mercer University School of Medicine, Macon, GA, USAMercer University School of Medicine, Macon, GA, USAVanderbilt University Medical Center, Nashville, TN, USAInstitute of Molecular Biology & Biophysics, Novosibirsk, Russian FederationMercer University School of Medicine, Macon, GA, USAVanderbilt University Medical Center, Nashville, TN, USAVanderbilt University Medical Center, Nashville, TN, USAVanderbilt University Medical Center, Nashville, TN, USAVanderbilt University Medical Center, Nashville, TN, USAVanderbilt University Medical Center, Nashville, TN, USAVanderbilt University Medical Center, Nashville, TN, USA; Corresponding author. Division of Clinical Pharmacology, Vanderbilt University Medical Center, 2220 Pierce Ave, PRB 554, Nashville, TN 37232, USA.Inflammation is a major cause of morbidity and mortality in Western societies. Despite use of multiple drugs, both chronic and acute inflammation still represent major health burdens. Inflammation produces highly reactive dicarbonyl lipid peroxidation products such as isolevuglandins which covalently modify and cross-link proteins via lysine residues. Mitochondrial dysfunction has been associated with inflammation; however, its molecular mechanisms and pathophysiological role are still obscure. We hypothesized that inflammation-induced isolevuglandins contribute to mitochondrial dysfunction and mortality. To test this hypothesis, we have (a) investigated the mitochondrial dysfunction in response to synthetic 15-E2-isolevuglandin (IsoLG) and its adducts; (b) developed a new mitochondria-targeted scavenger of isolevuglandins by conjugating 2-hydroxybenzylamine to the lipophilic cation triphenylphosphonium, (4-(4-aminomethyl)-3-hydroxyphenoxy)butyl)-triphenylphosphonium (mito2HOBA); (c) tested if mito2HOBA protects from mitochondrial dysfunction and mortality using a lipopolysaccharide model of inflammation. Acute exposure to either IsoLG or IsoLG adducts with lysine, ethanolamine or phosphatidylethanolamine inhibits mitochondrial respiration and attenuates Complex I activity. Complex II function was much more resistant to IsoLG. We confirmed that mito2HOBA markedly accumulates in isolated mitochondria and it is highly reactive with IsoLGs. To test the role of mitochondrial IsoLGs, we studied the therapeutic potential of mito2HOBA in lipopolysaccharide mouse model of sepsis. Mito2HOBA supplementation in drinking water (0.1 g/L) to lipopolysaccharide treated mice increased survival by 3-fold, improved complex I-mediated respiration, and histopathological analyses supported mito2HOBA-mediated protection of renal cortex from cell injury. These data support the role of mitochondrial IsoLG in mitochondrial dysfunction and inflammation. We conclude that reducing mitochondrial IsoLGs may be a promising therapeutic target in inflammation and conditions associated with mitochondrial oxidative stress and dysfunction. Keywords: Inflammation, Isolevuglandins, Mitochondrial dysfunction, Complex I, Respiration, Mortalityhttp://www.sciencedirect.com/science/article/pii/S221323171930480X
collection DOAJ
language English
format Article
sources DOAJ
author Vladimir Mayorov
Peter Uchakin
Venkataraman Amarnath
Alexander V. Panov
Christy C. Bridges
Roman Uzhachenko
Bill Zackert
Christy S. Moore
Sean Davies
Anna Dikalova
Sergey Dikalov
spellingShingle Vladimir Mayorov
Peter Uchakin
Venkataraman Amarnath
Alexander V. Panov
Christy C. Bridges
Roman Uzhachenko
Bill Zackert
Christy S. Moore
Sean Davies
Anna Dikalova
Sergey Dikalov
Targeting of reactive isolevuglandins in mitochondrial dysfunction and inflammation
Redox Biology
author_facet Vladimir Mayorov
Peter Uchakin
Venkataraman Amarnath
Alexander V. Panov
Christy C. Bridges
Roman Uzhachenko
Bill Zackert
Christy S. Moore
Sean Davies
Anna Dikalova
Sergey Dikalov
author_sort Vladimir Mayorov
title Targeting of reactive isolevuglandins in mitochondrial dysfunction and inflammation
title_short Targeting of reactive isolevuglandins in mitochondrial dysfunction and inflammation
title_full Targeting of reactive isolevuglandins in mitochondrial dysfunction and inflammation
title_fullStr Targeting of reactive isolevuglandins in mitochondrial dysfunction and inflammation
title_full_unstemmed Targeting of reactive isolevuglandins in mitochondrial dysfunction and inflammation
title_sort targeting of reactive isolevuglandins in mitochondrial dysfunction and inflammation
publisher Elsevier
series Redox Biology
issn 2213-2317
publishDate 2019-09-01
description Inflammation is a major cause of morbidity and mortality in Western societies. Despite use of multiple drugs, both chronic and acute inflammation still represent major health burdens. Inflammation produces highly reactive dicarbonyl lipid peroxidation products such as isolevuglandins which covalently modify and cross-link proteins via lysine residues. Mitochondrial dysfunction has been associated with inflammation; however, its molecular mechanisms and pathophysiological role are still obscure. We hypothesized that inflammation-induced isolevuglandins contribute to mitochondrial dysfunction and mortality. To test this hypothesis, we have (a) investigated the mitochondrial dysfunction in response to synthetic 15-E2-isolevuglandin (IsoLG) and its adducts; (b) developed a new mitochondria-targeted scavenger of isolevuglandins by conjugating 2-hydroxybenzylamine to the lipophilic cation triphenylphosphonium, (4-(4-aminomethyl)-3-hydroxyphenoxy)butyl)-triphenylphosphonium (mito2HOBA); (c) tested if mito2HOBA protects from mitochondrial dysfunction and mortality using a lipopolysaccharide model of inflammation. Acute exposure to either IsoLG or IsoLG adducts with lysine, ethanolamine or phosphatidylethanolamine inhibits mitochondrial respiration and attenuates Complex I activity. Complex II function was much more resistant to IsoLG. We confirmed that mito2HOBA markedly accumulates in isolated mitochondria and it is highly reactive with IsoLGs. To test the role of mitochondrial IsoLGs, we studied the therapeutic potential of mito2HOBA in lipopolysaccharide mouse model of sepsis. Mito2HOBA supplementation in drinking water (0.1 g/L) to lipopolysaccharide treated mice increased survival by 3-fold, improved complex I-mediated respiration, and histopathological analyses supported mito2HOBA-mediated protection of renal cortex from cell injury. These data support the role of mitochondrial IsoLG in mitochondrial dysfunction and inflammation. We conclude that reducing mitochondrial IsoLGs may be a promising therapeutic target in inflammation and conditions associated with mitochondrial oxidative stress and dysfunction. Keywords: Inflammation, Isolevuglandins, Mitochondrial dysfunction, Complex I, Respiration, Mortality
url http://www.sciencedirect.com/science/article/pii/S221323171930480X
work_keys_str_mv AT vladimirmayorov targetingofreactiveisolevuglandinsinmitochondrialdysfunctionandinflammation
AT peteruchakin targetingofreactiveisolevuglandinsinmitochondrialdysfunctionandinflammation
AT venkataramanamarnath targetingofreactiveisolevuglandinsinmitochondrialdysfunctionandinflammation
AT alexandervpanov targetingofreactiveisolevuglandinsinmitochondrialdysfunctionandinflammation
AT christycbridges targetingofreactiveisolevuglandinsinmitochondrialdysfunctionandinflammation
AT romanuzhachenko targetingofreactiveisolevuglandinsinmitochondrialdysfunctionandinflammation
AT billzackert targetingofreactiveisolevuglandinsinmitochondrialdysfunctionandinflammation
AT christysmoore targetingofreactiveisolevuglandinsinmitochondrialdysfunctionandinflammation
AT seandavies targetingofreactiveisolevuglandinsinmitochondrialdysfunctionandinflammation
AT annadikalova targetingofreactiveisolevuglandinsinmitochondrialdysfunctionandinflammation
AT sergeydikalov targetingofreactiveisolevuglandinsinmitochondrialdysfunctionandinflammation
_version_ 1725436039125794816